Dogwood Therapeutics (DWTX) Competitors $4.83 -0.12 (-2.42%) Closing price 03:59 PM EasternExtended Trading$4.80 -0.03 (-0.52%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock DWTX vs. ATHE, ACRV, VOR, EGRX, AKTX, ELYM, ESLA, XLO, LVTX, and LTRNShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Alterity Therapeutics (ATHE), Acrivon Therapeutics (ACRV), Vor Biopharma (VOR), Eagle Pharmaceuticals (EGRX), Akari Therapeutics (AKTX), Eliem Therapeutics (ELYM), Estrella Immunopharma (ESLA), Xilio Therapeutics (XLO), LAVA Therapeutics (LVTX), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Its Competitors Alterity Therapeutics Acrivon Therapeutics Vor Biopharma Eagle Pharmaceuticals Akari Therapeutics Eliem Therapeutics Estrella Immunopharma Xilio Therapeutics LAVA Therapeutics Lantern Pharma Alterity Therapeutics (NASDAQ:ATHE) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Do analysts prefer ATHE or DWTX? Alterity Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 197.03%. Dogwood Therapeutics has a consensus price target of $10.00, indicating a potential upside of 107.04%. Given Alterity Therapeutics' higher possible upside, equities analysts plainly believe Alterity Therapeutics is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in ATHE or DWTX? 2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 3.9% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer ATHE or DWTX? In the previous week, Alterity Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 1.87 indicating that Alterity Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Alterity Therapeutics Very Positive Dogwood Therapeutics Very Positive Which has more risk & volatility, ATHE or DWTX? Alterity Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Which has stronger earnings & valuation, ATHE or DWTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/ADogwood TherapeuticsN/AN/A-$12.35M-$18.04-0.27 Is ATHE or DWTX more profitable? Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Dogwood Therapeutics N/A N/A -34.74% SummaryAlterity Therapeutics and Dogwood Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.46M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.2721.1726.1419.88Price / SalesN/A278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book-0.647.518.055.38Net Income-$12.35M-$55.05M$3.15B$248.50M7 Day Performance0.63%2.45%1.85%2.97%1 Month Performance-8.35%7.33%4.81%6.02%1 Year PerformanceN/A5.38%34.86%20.39% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood Therapeutics2.0965 of 5 stars$4.83-2.4%$10.00+107.0%N/A$9.46MN/A-0.275Positive NewsATHEAlterity Therapeutics2.8541 of 5 stars$4.37+4.0%$12.00+174.6%+126.9%$37.24MN/A0.0010Gap UpACRVAcrivon Therapeutics3.1335 of 5 stars$1.18flat$17.71+1,401.2%-79.0%$37MN/A-0.5358Positive NewsVORVor Biopharma3.9957 of 5 stars$0.29+20.7%$7.06+2,333.5%+44.5%$36.24MN/A-0.18140Analyst UpgradeAnalyst RevisionGap UpHigh Trading VolumeEGRXEagle Pharmaceuticals2.2246 of 5 stars$2.79-3.0%N/A-57.3%$36.23M$257.55M0.00100Gap UpAKTXAkari Therapeutics1.6112 of 5 stars$1.16+3.6%N/A-64.2%$36.04MN/A0.009News CoverageELYMEliem TherapeuticsN/A$1.21-1.6%N/A-82.4%$36MN/A-2.289ESLAEstrella Immunopharma2.4717 of 5 stars$0.92-7.1%$16.00+1,639.1%-21.7%$35.80MN/A-3.54N/APositive NewsGap UpXLOXilio Therapeutics2.9604 of 5 stars$0.67-2.7%$4.00+497.0%-25.0%$35.65M$6.34M-0.8070Positive NewsLVTXLAVA Therapeutics2.1079 of 5 stars$1.33+1.1%$3.17+139.0%-28.4%$34.46M$11.98M-1.2760Positive NewsGap UpLTRNLantern Pharma2.2831 of 5 stars$3.07-3.5%$25.00+714.3%-30.3%$34.30MN/A-1.6720Gap Down Related Companies and Tools Related Companies ATHE Alternatives ACRV Alternatives VOR Alternatives EGRX Alternatives AKTX Alternatives ELYM Alternatives ESLA Alternatives XLO Alternatives LVTX Alternatives LTRN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
